- Demographic and clinical data of patients with myasthenia gravis. N=147
| Characteristics | n (%) |
|---|---|
| Age in years Mean±SD | 34.2±16.6 |
| Disease duration in months Mean±SD | 25.7±8.9 |
| Gender | |
| Male | 40 (27.2) |
| Female | 107 (72.8) |
| Clinical presentation | |
| Ocular | 84 (57.1) |
| Bulbar | 40 (27.2) |
| Generalized | 23 (15.6) |
| Anti AChR antibody | |
| Positive | 130 (88.4) |
| Anti-MuSK antibody | |
| Positive | 8 (5.4) |
| Double seronegative | 11 (7.5) |
| RNS | |
| Decremental response | 65 (44.2) |
| Normal | 24 (16.3) |
| Not done | 58 (39.5) |
| Treatment | |
| Pyridostigmine | 14 (9.5) |
| Azathioprine | 4 (2.7) |
| Pyridostigmine, prednisolone, with or without azathioprine | 94 (63.9) |
| Pyridostigmine, prednisolone, with or without azathioprine, and one dose IVIg | 10 (6.8) |
| Pyridostigmine, prednisolone, and mycophenolate | 11 (7.5) |
| Pyridostigmine, prednisolone, with or without azathioprine, and monthly IVIg | 14 (9.5) |
| Thymectomy | |
| Done | 92 (62.6) |
| Not done | 55 (37.4) |
| Treatment response | |
| Controlled | 101 (68.7) |
| Not controlled | 46 (31.3) |
| CT chest | |
| Prominent thymus | 30 (20.4) |
| Thymoma | 17 (11.6) |
| Normal | 100 (68.0) |
| Histopathology | |
| Thymic hyperplasia | 57 (38.8) |
| Thymoma | 13 (8.8) |
| Normal | 22 (15) |
| Clinical state at the end of follow up | |
| Ocular | 7 (4.8) |
| Bulbar | 4 (2.7) |
| Generalized | 136 (92.5) |
| Family history of MG | |
| Positive | 6 (4.1) |
| Negative | 95 (64.6) |
| Not recorded | 46 (31.3) |
MG- Myasthenia gravis, AChR-acetylcholine receptors, RNS - repetitive nerve stimulation